Complete blood count risk score and its components,including RDW,are associated with mortality in the JUPITER trial

Abstract

Background

Previously, we showed that sex-specific complete blood count (CBC) risk scores strongly predicted risk of all-cause mortality in multiple sets of general medical patients. This study evaluated the CBC risk score in an independent, well-studied international primary risk population of lower-risk individuals initially free from cardiovascular (CV) disease.

Design

Observational secondary analysis of a randomized trial population.

Methods

The previously derived and validated CBC score was evaluated for association with all-cause mortality among CV disease-free females (n = 6568) and males (n = 10,629) enrolled for up to 5 years in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Associations of the CBC score with CV mortality and with major CV disease were also tested.

Results

The CBC score predicted all-cause mortality, with univariable hazard ratio (HR) 4.83 (95% CI 3.70–6.31) for the third CBC score tertile vs. the first tertile, and HR 2.31 (CI 1.75–3.05) for the second tertile (p_trend < 0.001). The CBC score retained significance after adjustment: HR 1.97 (CI 1.46–2.67) and 1.51 (CI 1.13–2.00) for tertiles 3 and 2 vs. 1, respectively (p_trend < 0.001). The CBC score also predicted CV mortality (p_trend = 0.025) and the primary JUPITER endpoint (p_trend = 0.015). c-statistics for mortality were 0.729 among all, and 0.722 and 0.750 for females and males, respectively.

Conclusions

The CBC risk score was strongly associated with all-cause mortality among JUPITER trial participants and had good discrimination. It also predicted CV-specific outcomes. This CBC score may be useful in identifying cardiac disease-free individuals at increased risk of mortality.

Keywords

CBC clinical decision rule clinical prediction rule red cell distribution width

Get full access to this article

View all access options for this article.

References

Anderson

Ronnow

Horne

. Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease. Am J Cardiol 2007; 99: 169–174.

Horne

Anderson

John

. Which white blood cell compartments predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45: 1638–1643.

Walsh

Cook

Goulder

. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181–184.

Forhecz

Gombos

Borgulya

. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J 2009; 158: 659–666.

Azab

Torbey

Hatoum

. Usefulness of red cell distribution width in predicting all-cause longterm mortality after non-ST-elevation myocardial infarction. Cardiology 2011; 119: 72–80.

Horne

May

Kfoury

. The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. Eur J Heart Fail 2010; 12: 1203–1213.

Horne

May

Muhlestein

. Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med 2009; 122: 550–558.

Ridker

Danielson

Fonseca

FAH

. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–2207.

Ridker

. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108: 2292–2297.

10.

Ridker

Fonseca

Genest

. JUPITER Trial Study Group. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007; 100: 1659–1664.

11.

Cooney

Dudina

Graham

. Value and limitations of existing scores for the assessment of cardiovascular risk. J Am Coll Cardiol 2009; 54: 1209–1222.

12.

Müller-Riemenschneider

Holmberg

Rieckmann

. Barriers to routine risk-score use for healthy primary care patients. Arch Intern Med 2010; 170: 719–724.

13.

Grady

Berkowitz

. Why is a good clinical prediction rule so hard to find? Arch Intern Med 2011; 171: 1701–1702.

14.

Tokgozoglu

Bruckert

. Implementation, target population, compliance and barriers to risk guided therapy. Eur J Prev Cardiol 2012; 19(S2): 37–41.

15.

Horne

. The red cell distribution width: What is its value for risk prognostication and for understanding disease pathophysiology? Cardiology 2011; 119: 140–141.

16.

Patel

Ferrucci

Ershler

. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med 2009; 169: 515–523.

17.

Braun

Domany

Kenig

. Elevated red cell distribution width predicts poor outcome in young patients with community acquired pneumonia. Crit Care 2011; 15: R194–R202.

18.

Park

Kim

. Red blood cell distribution width is an independent predictor of mortality in acute kidney injury patients treated with continuous renal replacement therapy. Nephrol Dial Transplant 2012; 27: 589–594.

19.

Majercik

Fox

Knight

. Red cell distribution width is predictive of mortality in trauma patients. J Trauma Acute Care Surg 2013; 74: 1021–1026.

20.

Horne

Hegewald

Muhlestein

. The red cell distribution width strongly predicts mortality among patients evaluated by pulmonary function testing. Chest 2012; 142(suppl): 667A–667A. (abstract).

21.

Morris

Algorithm based decision making. In: Tobin

(eds). Principles and practice of intensive care monitoring, New York: McGraw-Hill, 1997, pp. 1355–1381.

22.

Horne

Knight

May

. Panoptic total cardiovascular risk prediction using all possible predictors versus clinically optimized risk assessment using variable subsets: A review. Future Cardiol 2012; 8: 765–778.

23.

Cui

Forbes

Kirby

. Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID study. Eur J Cardiovasc Prev Rehab 2009; 16: 660–668.